Annovis Bio Files for FDA Orphan Drug Designation for ANVS401 for the Treatment of Alzheimer’s Disease in Persons with Down Syndrome

By WebmasterMay 13, 2021November 1st, 2024No Comments

Annovis Bio Files for FDA Orphan Drug Designation for ANVS401 for the Treatment of Alzheimer’s Disease in Persons with Down Syndrome

Previous PostAnnovis Bio Appoints Accomplished Neuroscientist Dr. Cheng Fang as VP of Research
Next PostImmunome Reports First Quarter 2021 Financial Results